ProCE Banner Activity

Healthcare Provider Awareness and Integration of Immunotherapy for Stage III NSCLC


This poster, presented at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, reports an analysis of healthcare provider uptake of immune checkpoint inhibitor therapy for the treatment of unresectable stage III NSCLC in the 9 months following its approval. Self-reported practice trends at baseline showed that most HCPs were not optimally treating unresectable stage III NSCLC prior to attending the symposia. However, post-education data suggest that HCPs are willing to modify their practice in this setting after receiving expert led education and guidance.

Released: February 26, 2019

Expiration: February 25, 2020

No longer available for credit.


Additional Information

Tradd Sanderson
Director of Marketing
Clinical Care Options
Telephone: 855.224.2241